Teva Pharmaceutical Industries Ltd (TEVA) to Release Quarterly Earnings on Thursday
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) will announce its Q313 earnings results on Thursday, October 31st. Analysts expect the company to announce earnings of $1.26 per share and revenue of $5.00 billion for the quarter.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.20. The company had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.94 billion. During the same quarter in the previous year, the company posted $1.28 earnings per share. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, analysts expect Teva Pharmaceutical Industries Ltd to post $5.00 EPS for the current fiscal year and $5.16 EPS for the next fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) traded down 6.36% on Wednesday, hitting $38.41. 29,682,646 shares of the company’s stock traded hands. Teva Pharmaceutical Industries Ltd has a 52-week low of $36.63 and a 52-week high of $42.83. The stock has a 50-day moving average of $38.99 and a 200-day moving average of $39.13. The company has a market cap of $32.456 billion and a price-to-earnings ratio of 84.23.
A number of research firms have recently commented on TEVA. Analysts at Goldman Sachs Group Inc. reiterated a “sell” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Wednesday. On a related note, analysts at Citigroup Inc. initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Friday, October 25th. They set a “buy” rating and a $47.00 price target on the stock. Finally, analysts at Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday, October 14th. They set a “market perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $45.56.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.